The major advantage of Hsp inhibitors is that constitutive Hsp90 upregulation is a tumor-specific characteristic, not present in normal cells, which should lead to reduced side effects [8,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]. The gene discussed is HSP90B2P; the disease is neoplasm.